BS_H4NXBD2D
Supratentorial Ependymoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Supratentorial Ependymoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Supratentorial Ependymoma
- age_years
- 2.099
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.538
- E2F_TARGETS+0.488
- PROTEIN_SECRETION+0.430
- G2M_CHECKPOINT+0.418
- MTORC1_SIGNALING+0.409
- DNA_REPAIR+0.372
- UNFOLDED_PROTEIN_RESPONSE+0.352
- MYC_TARGETS_V2+0.351
- OXIDATIVE_PHOSPHORYLATION+0.310
- CHOLESTEROL_HOMEOSTASIS+0.223
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.438
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.434
- COAGULATION-0.430
- INFLAMMATORY_RESPONSE-0.406
- MYOGENESIS-0.398
- IL6_JAK_STAT3_SIGNALING-0.368
- COMPLEMENT-0.364
- APICAL_SURFACE-0.354
- KRAS_SIGNALING_DN-0.316
- IL2_STAT5_SIGNALING-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_G23JJAZY | Supratentorial Ependymoma | — | 0.917 |
| 2 | BS_7G42J2SK | Supratentorial Ependymoma | — | 0.914 |
| 3 | TCGA-DK-A3IS-01A-21R-A21D-07 | — | — | 0.907 |
| 4 | BS_FTKPQ5FZ | Supratentorial Ependymoma | — | 0.904 |
| 5 | TCGA-4Z-AA80-01A-11R-A39I-07 | — | — | 0.903 |
| 6 | BS_KSKZ9J7J | Embryonal tumors | — | 0.901 |
| 7 | BS_G23JJAZY | EPN | Supratentorial EPN | 0.892 |
| 8 | BS_74G5K7JF | Supratentorial Ependymoma | — | 0.889 |
| 9 | BS_052PZFMK | high-grade glioma | — | 0.881 |
| 10 | TCGA-58-A46K-01A-11R-A24H-07 | — | cohortSQ2 | 0.880 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.538 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.488 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.430 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.418 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.409 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.372 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.352 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.351 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.310 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.223 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.212 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.202 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.176 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.166 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.133 | Inavolisib | — uncovered |
| PEROXISOME | 0.090 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.087 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.085 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.072 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.070 | Idelalisib | — uncovered |